Jazz Pharmaceuticals (JAZZ) Non-Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $7.3 billion for Q1 2026.

• In Q1 2026, Non-Current Assets fell 1.76% year-over-year to $7.3 billion; the TTM figure through Mar 2026 stood at $30.0 billion (down 1.22% YoY), while the FY2025 annual figure was $7.5 billion, up 1.49% from the prior year.
• Non-Current Assets for Q1 2026 stood at $7.3 billion, down from $7.5 billion in the prior quarter.
• The five-year high for Non-Current Assets was $9.3 billion in Q1 2022, with the low at $7.3 billion in Q1 2026.
• The 5-year median for Non-Current Assets is $7.8 billion (2022), against an average of $7.9 billion.
• Peak annual rise in Non-Current Assets reached 158.19% in 2022, while the deepest fall reached 20.68% in 2022.
• Jazz Pharmaceuticals' Non-Current Assets stood at $8.2 billion in 2022, then declined by 3.3% to $8.0 billion in 2023, then fell by 7.22% to $7.4 billion in 2024, then grew by 1.49% to $7.5 billion in 2025, then dropped by 2.89% to $7.3 billion in 2026.
• Business Quant data shows JAZZ's Non-Current Assets at $7.3 billion in Q1 2026, $7.5 billion in Q4 2025, and $7.6 billion in Q3 2025.